2,3-XP

2,3-Dimethylphenylpiperazine (2,3-DMPP; code name PAL-218) is a monoamine releasing agent and designer drug of the phenylpiperazine family. It acts as a partial serotonin–norepinephrine releasing agent (SNRA), with EC50Tooltip half-maximal effective concentration (EmaxTooltip maximal efficacy) values of 24 to 26 nM (85%) for serotonin, 13.7 to 56 nM (62%) for norepinephrine, and 1,207 to 1,320 nM (66%) for dopamine (22–96-fold lower than serotonin and norepinephrine). Its possible activities at serotonin receptors were not reported. The drug was first described in the scientific literature by 2009.

Also known as: 1-(2,3-dichlorophenyl)piperazine

Classification

Chemical: Piperazine

Effects

Stimulation
Nausea
Increased Heart Rate
Insomnia
Headache
Pupil Dilation
Talkativeness
Alertness Enhancement
Euphoria
Anxiety
Mood Lift
Increased Sociability
Light Sensitivity
Appetite Suppression
Visual Distortion
Open Eye Visuals
Patterning
Blurred Vision

Routes of Administration

No route information available yet.

Harm Reduction

Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.

Sources

Substance data is aggregated from the following public harm-reduction and reference sources.

wikipedia.org

Links

This static page is intended as a readable non-JS and prerender-friendly library export.

Get the full DrugsPRO experience

Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.

Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu